Skip to main content
. 2016 Jun 28;8(2):6165. doi: 10.4081/rt.2016.6165

Table 4.

Summary of relevant prior studies with survival data and treatment with radiation therapy data.

Institution, Country Authors, year Study dates Patients, no. Angio, % Rhabdo, % Med FU, y Tx with RT, % RT regimen Median dose, Gy LC or LRC, % (y) DM, % (y) DFS, % (y) OS,) % (y)
MGH, USA Willers et al.,15 1995 1972-1993 57 19 0 4.3 100 Preoperative, postoperative, definitive 64.80 LRC: 60(5) 23(5) NR 66(5)
TMH, India Dudhat et al.,5 2000 1981-1995 72 0 0 NR 53 Postoperative NR NR NR 45(5) 60(5)
University of Miami, USA Chen et al.,19 2005 1996-2003 39 0 10 8.7 100 Preoperative, postoperative, definitive NR 78(5) 63(5)
University, of Florida USA Trifiletti et al.,13 2012 1981-2009 24 0 0 11.1 100 Postoperative 64.80 LC: 73(10) 0(10) 73(10) 73(10)
IRCCS, Italy Mattavelli et al.,9 2013 1990-2010 167 5 0 5.5 36 Preoperative, postoperative NR LC: 81(10) 11(10) NR NR
AMC, South Korea Park et al.,17 2014 1995-2012 122 12 20 6 53 Postoperative, definitive 60.00 LRC: 76(5), 64(10) NR NR 75(5), 66(10)
NCCS, Singapore Yeang et al.,16 2013 2002-2011 83 16 6 6.9 53 Postoperative, definitive NR LRC: 49(5) 29(5) 37(5) 45(5)
University of Washington, USA Chang,18 2014 2000-2012 97 23 11 1.8 55 Preoperative, Postoperative, Definitive NR NR NR NR 78(5)
Present study Vitzthum et al. 1998-2012 48 29 2 4.8 100 Preoperative, postoperative, definitive 60.00 LC: 87(5) LRC: 73(5) 16(5) 63(5) 83(5)

AMC, Asan Medical Center; Angio, angiosarcoma; DM, distant metastasis; DFS, disease-free survival; IRCCS, Fondazione Instituto Nazionale del Tumori; LC, local control; LRC, locoregional control; Med FU, median follow-up; MGH, Massachusetts General Hospital; NCCS, National Cancer Centre Singapore; NR, not reported; OS, overall survival; Rhabdo, rhabdomyosarcoma; RT, radiation therapy; TMH, Tata Memorial Hospital; Tx with RT, treatment (or treated) with radiation therapy.